In Vitro Antibacterial Activity of the Pyrrolopyrazolyl-Substituted Oxazolidinone RWJ-416457 | Zendy

Barbara D. Foleno | Zendy; Darren Abbanat | Zendy; Raúl Goldschmidt | Zendy; Robert K. Flamm | Zendy; Steve D. Paget | Zendy; Glenda C. Webb | Zendy; Ellyn Wira | Zendy; Mark J. Macielag | Zendy; Karen Bush | Zendy

AI Assistant Blog Pricing

Home ZAIA Blog

Open Access

In Vitro Antibacterial Activity of the Pyrrolopyrazolyl-Substituted Oxazolidinone RWJ-416457

Author(s) -

Barbara D. Foleno,

Darren Abbanat,

Raúl Goldschmidt,

Robert K. Flamm,

Steve D. Paget,

Glenda C. Webb,

Ellyn Wira,

Mark J. Macielag,

Karen Bush

Publication year - 2006

Publication title -

antimicrobial agents and chemotherapy

Language(s) - English

Resource type - Journals

SCImago Journal Rank - 2.07

H-Index - 259

eISSN - 1070-6283

pISSN - 0066-4804

DOI - 10.1128/aac.01017-06

Subject(s) - linezolid , potency , in vitro , microbiology and biotechnology , antibacterial agent , pharmacology , chemistry , staphylococcus aureus , antibiotics , biology , bacteria , biochemistry , vancomycin , genetics

RWJ-416457, an investigational pyrrolopyrazolyl-substituted oxazolidinone, inhibited the growth of linezolid-susceptible staphylococci, enterococci, and streptococci at concentrations of ≤4 μg/ml, generally exhibiting two- to fourfold-greater potency than that of linezolid. Time-kill studies demonstrated bacteriostatic effects for both RWJ-416457 and linezolid.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.

Having issues? You can contact us here

Accelerating Research